Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
2.530
+0.030 (1.20%)
At close: Sep 30, 2026, 4:00 PM EDT
2.520
-0.010 (-0.40%)
After-hours: Sep 30, 2026, 5:45 PM EDT
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 33 employees as of December 31, 2025. The number of employees increased by 2 or 6.45% compared to the previous year.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-$2,986,697
Market Cap
205.79M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 33 | 2 | 6.45% | 33 | 0 |
| Dec 31, 2024 | 31 | 11 | 55.00% | 31 | 0 |
| Dec 31, 2023 | 20 | 3 | 17.65% | 20 | 0 |
| Dec 31, 2022 | 17 | 5 | 41.67% | 17 | 0 |
| Dec 31, 2021 | 12 | 2 | 20.00% | 12 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Entrada Therapeutics | 152 |
| Foghorn Therapeutics | 106 |
| Alector | 103 |
| Cartesian Therapeutics | 75 |
| Compugen | 75 |
| Anavex Life Sciences | 34 |
| Whitehawk Therapeutics | 32 |
ELDN News
- 8 days ago - Eledon Pharmaceuticals updates long-term data from Phase 2 BESTOW trial - TheFly
- 8 days ago - Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society - GlobeNewsWire
- 21 days ago - Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society - GlobeNewsWire
- 27 days ago - Eledon files islet cell transplant application, plans Phase 3 kidney trial - TheFly
- 27 days ago - Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 - GlobeNewsWire
- 6 weeks ago - Eledon Pharmaceuticals reports Q2 EPS (27c), consensus (15c) - TheFly
- 6 weeks ago - Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 weeks ago - Eledon Pharmaceuticals Earnings release: Q2 2026 - Filings